P. Ang et al., Use of a peripherally implanted subcutaneous permanent central venous access device for chemotherapy - the Singapore General Hospital experience, AUST NZ J M, 30(4), 2000, pp. 470-474
Citations number
21
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: Venous access for chemotherapy patients at the Singapore Genera
l Hospital has conventionally been via an externalised (Hickman) catheter.
A peripherally implanted permanent subcutaneous central venous access devic
e (P.A.S.Port) was introduced in 1996.
Aims: We review its use, complications and cost competitiveness with other
chemotherapy delivery systems.
Methods: A retrospective study of clinical records was conducted with fello
w up interviews of patients and nursing staff.
Results: Twelve patients had the P.A.S.Port inserted for administration of
chemotherapy as an outpatient procedure. Immediate complications were pain
(8%) and bruising (8%). One port-related infection (8%) one week following
insertion was reported and one patient complained of interference with elbo
w movement as a late complication. Cost analysis was favourable for P.A.S.P
ort over an externalised Hickman catheter or chest-placed port at one year.
Patient and nursing staff acceptance was high.
Conclusion: P.A.S.Port insertion is a safe outpatient procedure and is an a
lternative for permanent venous access.